Preclinical data suggest the upregulation of DTIC via administrating pan-PI3K inhibitor (BKM120), and its synergistic effect with anti-PD-1 in the mouse model bearing breast cancer or muscle-invasive bladder cancer patient-derived xenograft [58, 59]. This evidence concerns the gene PIK3CA and breast carcinoma.